What to watch for as Novartis heads to the FDA with a novel cancer therapy

(By Damian Garde and Adam Feurerstein for STAT)

The FDA has weighed in on Novartis’ pioneering personalized cancer therapy, which looks almost certain to win approval. But the agency is wading into uncharted territory, bringing along a bevy a questions on manufacturing and long-term safety to a hotly anticipated public forum. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.